Literature DB >> 12446973

AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576.

Carola Otth1, Ilona I Concha, Thomas Arendt, Jens Stieler, Reinhard Schliebs, Christian González-Billault, Ricardo B Maccioni.   

Abstract

Previous studies of Abeta-induced neuronal damage of hippocampal cells in culture have provided strong evidence that deregulation of the Cdk5/p35 kinase system is involved in the neurodegeneration pathway. Cdk5 inhibitors and antisense probes neuroprotected hippocampal cells against the neurotoxic action of Abeta. To further investigate the mechanisms underlying the participation of Cdk5 in neuronal degeneration, the transgenic mouse containing the Swedish mutations, Tg2576, was used as an animal model. Immunocytochemical studies using anti-Abeta(1-17) antibody evidenced the presence of labeled small-clustered core plaques in the hippocampus and cortex of 18-month-old transgenic mice brains. The loss of granular cells without a compressed appearance was detected in the vicinity of the cores in the dentate gyrus of the hippocampus. Immunostaining of Tg2576 brain sections with antibodies AT8, PHF1 and GFAP labeled punctuate dystrophic neurites in and around the amyloid core. Reactive astrogliosis around the plaques in the hippocampus was also observed. Studies at the molecular level showed differences in the expression of the truncated Cdk5 activator p25 in the transgenic animal, as compared with wild type controls. However no differences in Cdk5 levels were detected, thus corroborating previous cellular findings. Interestingly, hyperphosphorylated tau epitopes were substantially increased as assessed with the AT8 and PHF1 antibodies, in agreement with the observation of a p25 increase in the transgenic animal. These observations strongly suggest that the increased exposure of Alzheimer's type tau phosphoepitopes in the transgenic mice correlated with deregulation of Cdk5 leading to an increase in p25 levels. These studies also provide further evidence on the links between extraneuronal amyloid deposition and tau pathology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446973     DOI: 10.3233/jad-2002-4508

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  32 in total

Review 1.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

2.  S-nitrosylation of Cdk5: potential implications in amyloid-β-related neurotoxicity in Alzheimer disease.

Authors:  Jing Qu; Tomohiro Nakamura; Emily A Holland; Scott R McKercher; Stuart A Lipton
Journal:  Prion       Date:  2012-08-09       Impact factor: 3.931

3.  Special Issue on "Cdk5 and Brain Disorders": Prologue.

Authors:  Jyotshnabala Kanungo
Journal:  Brain Disord Ther       Date:  2012-05-31

Review 4.  The role of inflammasome in Alzheimer's disease.

Authors:  Li Liu; Christina Chan
Journal:  Ageing Res Rev       Date:  2014-02-19       Impact factor: 10.895

5.  Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.

Authors:  Min Zhang; Jin Li; Paramita Chakrabarty; Bitao Bu; Inez Vincent
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

6.  Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.

Authors:  Bingqian Liu; Suhail Rasool; Zhikuan Yang; Charles G Glabe; Steven S Schreiber; Jian Ge; Zhiqun Tan
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

7.  p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.

Authors:  Lingyan Zhang; Wen Liu; Karen K Szumlinski; John Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-14       Impact factor: 11.205

8.  Loss of Endothelial Nitric Oxide Synthase Promotes p25 Generation and Tau Phosphorylation in a Murine Model of Alzheimer's Disease.

Authors:  Susan A Austin; Zvonimir S Katusic
Journal:  Circ Res       Date:  2016-09-06       Impact factor: 17.367

Review 9.  TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease.

Authors:  Filippo Caraci; Giuseppe Battaglia; Valeria Bruno; Paolo Bosco; Viviana Carbonaro; Maria Laura Giuffrida; Filippo Drago; Maria Angela Sortino; Ferdinando Nicoletti; Agata Copani
Journal:  CNS Neurosci Ther       Date:  2009-11-19       Impact factor: 5.243

10.  In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice.

Authors:  Jose Morales-Corraliza; Matthew J Mazzella; Jason D Berger; Nicole S Diaz; Jennifer H K Choi; Efrat Levy; Yasuji Matsuoka; Emmanuel Planel; Paul M Mathews
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.